ALNYLAM PHARMACEUTICALS INC

Alnylam’s Q2 2026 results turn a net loss into $164 M profit, powered by a 37 % jump in AMVUTTRA sales, yet a revised revenue outlook and market drop expose risks and opportunities for growth.

Alnylam strengthens its RNA‑medicine pipeline by adding Dr. Laura Sepp‑Lorenzino to the Scientific Advisory Board, boosting CRISPR‑RNAi expertise and clinical‑trial strategy.

Alnylam’s late‑stage HCM trial setback drops shares, yet its diversified RNAi pipeline and strong oncology prospects keep investor optimism alive.

Alnylam boosts its R&D pipeline with a tech partnership and milestone‑based licensing, accelerating discovery, diversifying therapy focus, and strengthening cash flow.

Alnylam expands its RNAi distribution to Scandinavia, boosting access to rare‑disease therapies and rare‑cardiomyopathy treatments across 17 European markets.

Alnylam’s board expansion and governance upgrades boost scientific expertise and shareholder confidence, positioning the company for stronger market access, M&A, and RNA‑i drug success.

Alnylam Pharmaceuticals: contrasting analyst views, robust pipeline, regulatory shifts, and market risks explained – find out why investors should watch Q3 earnings.

Alnylam Pharmaceuticals’ recent share dip reflects broader market sentiment, but regulatory tightening and fierce RNA‑tech competition may shape its future trajectory.

Alnylam’s April 6 filings reveal solid governance, an insider share sale, and potential S&P 500 inclusion—showing how its RNA‑interference platform fuels future growth.

Alnylam Pharmaceuticals shares rise with tech‑biotech rally, but gains driven by market momentum; analysts keep “Buy” ratings and target $425‑$510 per share.